

**EFFECTIVE DATE:** 05|01|2026

**POLICY LAST REVIEWED:** 01|21|2026

## OVERVIEW

Radiofrequency ablation (RFA) and cryoneurolysis of nerves have been proposed as treatments for several different types of pain. RFA has been used to treat a number of clinical pain syndromes such as trigeminal neuralgia as well as cervical and lumbar pain. This review evaluates the application of RFA and cryoneurolysis in peripheral sites distant from the spine.

Morton neuroma is a common and painful compression neuropathy of the dorsal foot that is also referred to as intermetatarsal neuroma, interdigital neuroma, interdigital neuritis, and Morton metatarsalgia. Morton neuroma has been treated with conservative measures (pads, orthotics, drugs) or surgery. Minimally invasive procedures, including intralesional alcohol injection, radiofrequency ablation (RFA) and cryoablation, have been investigated as alternatives to open surgery. These methods have also been used to treat other peripheral neuromas.

## MEDICAL CRITERIA

Peripheral Nerve CPT Code 64640

### **Medicare Advantage Plans and Commercial Products**

Peripheral nerve or branch ablation may be considered medically necessary when the criteria in the online tool is met. Please refer to the Prior Authorization of Services, Treatments or Procedures policy for the appropriate clinical criteria source.

Genicular Nerve CPT Code 64624

### **Medicare Advantage Plans and Commercial Products**

Not applicable.

Other Nerves/Neuromas CPT Codes 64632, 0440T – 0442T

### **Medicare Advantage Plans and Commercial Products**

Not applicable.

Device HCPCS Codes C9808, C9809

### **Medicare Advantage Plans**

Nerve cryoablation probe and cryoablation needle may be considered medically necessary when the associated procedure is determined to be medically necessary AND when the criteria in the Medical Necessity policy is met. Refer to the Related Policies section.

### **Commercial Products**

Not applicable.

## PRIOR AUTHORIZATION

Peripheral Nerve CPT Code 64640

### **Medicare Advantage Plans and Commercial Products**

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products via the online tool for participating providers.

Genicular Nerve CPT Code 64624

**Medicare Advantage Plans and Commercial Products**

Not applicable.

Other Nerves/Neuromas CPT Codes 64632, 0440T – 0442T

**Medicare Advantage Plans and Commercial Products**

Not applicable.

Device HCPCS Codes C9808, C9809

**Medicare Advantage Plans**

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products.

**Commercial Products**

Not applicable.

**POLICY STATEMENT**

Peripheral Nerve CPT Code 64640

**Medicare Advantage Plans and Commercial Products**

Because CPT code 64640 is used to represent ablation of peripheral nerve, but is not specific to a particular method of treatment (i.e. radiofrequency or cryoneurolysis), medical necessity review is needed to determine specifically what procedure is being performed.

Peripheral nerve or branch ablation may be considered medically necessary when the criteria in the online tool is met. Please refer to the Prior Authorization of Services, Treatments or Procedures policy for the appropriate clinical criteria source.

Cryoneurolysis of peripheral nerves to treat pain associated with knee osteoarthritis or total knee arthroplasty is not covered for Medicare Advantage Plans and not medically necessary for Commercial Products as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Radiofrequency ablation or cryoneurolysis of peripheral nerves to treat pain associated with occipital neuralgia or cervicogenic headache is not covered for Medicare Advantage Plans and not medically necessary for Commercial Products as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Genicular Nerve CPT Code 64624

**Medicare Advantage Plans**

Ablation of the genicular nerve (radiofrequency or cryoneurolysis) is covered.

**Commercial Products**

Ablation of the genicular nerve (radiofrequency or cryoneurolysis) is not medically necessary as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Other Nerves/Neuromas CPT Codes 64632, 0440T – 0442T

**Medicare Advantage Plans**

Minimally invasive ablation procedures, including intralesional alcohol injection, radiofrequency ablation, and cryoablation, are not covered for the treatment of Morton and other peripheral neuromas as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

**Commercial Products**

Minimally invasive ablation procedures, including intralesional alcohol injection, radiofrequency ablation, and cryoablation, are not medically necessary for the treatment of Morton and other peripheral neuromas as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### Device HCPCS Codes C9808, C9809

#### **Medicare Advantage Plans**

Nerve cryoablation probe and cryoablation needle may be considered medically necessary when the associated procedure is determined to be medically necessary and when the criteria in the Medical Necessity policy is met. Refer to the Related Policies section.

#### **Commercial Products**

Nerve cryoablation probe and cryoablation needle are not medically necessary as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **COVERAGE**

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable surgery and not medically necessary/not covered benefits/coverage.

#### **BACKGROUND**

##### **Nerve Radiofrequency Ablation**

Nerve radiofrequency ablation (RFA) is a minimally invasive method that involves the use of heat and coagulation necrosis to destroy tissue. A needle electrode is inserted through the skin and into the tissue to be ablated. A high-frequency electrical current is applied to the target tissue and a small sphere of tissue is coagulated around the needle by the heat generated. It is theorized that the thermal lesioning of the nerve destroys peripheral sensory nerve endings, resulting in the alleviation of pain. Cooled RFA is a variation of nerve RFA using a water-cooled probe that applies more energy at the desired location without excessive heat diffusing beyond the area, causing less tissue damage away from the nerve. The goal of ablating the nerve is the same.

RFA is also distinguished from pulsed radiofrequency (RF) treatment, which has been investigated for different types of pain. The mechanism of action of pulsed RF treatment is uncertain but it is thought not to destroy the nerve. It does produce some degree of nerve destruction but is thought to cause less damage than standard RFA. Some studies refer to pulsed RF treatment as ablation.

##### **Cryoneurolysis**

Cryoneurolysis is being investigated to alleviate pain. Temperatures of -20° to -100°C applied to a nerve cause Wallerian (anterograde axonal) degeneration, with disruption of nerve structure and conduction but maintenance of the perineural and epineural elements of the nerve bundle. Wallerian degeneration allows complete regeneration and recovery of nerve function in about 3 to 5 months. The iovera<sup>®</sup> cryoablation system is a portable handheld device that applies percutaneous and targeted delivery of cold to superficial peripheral nerves.

##### **Neuroma**

A neuroma is a pathology of a peripheral nerve that develops as part of a normal reparative process. Neuromas may develop after nerve injury or result from chronic irritation, pressure, stretch, poor repair of nerve lesions or previous neuromas, laceration, crush injury, or blunt trauma. Neuromas typically appear 6 to 10 weeks after trauma, with most presenting within 1 to 12 months after injury or surgery. They may gradually enlarge over 2 to 3 years and may or may not be painful. Pain from a neuroma may be secondary to traction on the nerve by scar tissue, compression of the sensitive nerve endings by adjacent soft tissues, ischemia of the nervous tissue, or ectopic foci of ion channels that elicit neuropathic pain. Patients may describe the pain as low-intensity dull pain or intense paroxysmal burning pain, often triggered by external stimuli such as touch or temperature. Neuroma formation has been implicated as a contributor of

neuropathic pain in residual limb pain, post thoracotomy, postmastectomy, and post herniorrhaphy pain syndromes. Neuromas may coexist with phantom pain or can predispose to it.

### **Morton Neuroma**

Morton neuroma is a common and painful compression neuropathy of the common digital nerve of the foot that may also be referred to as interdigital neuroma, interdigital neuritis, and interdigital or Morton metatarsalgia. It is histologically characterized by perineural fibrosis, endoneurial edema, axonal degeneration, and local vascular proliferation. Thus, some investigators do not consider Morton neuroma to be a true neuroma; instead, they consider it to be an entrapment neuropathy occurring secondary to compression of the common digital nerve under the overlying transverse metatarsal ligament. Morton neuroma appears 10-fold more often in women than in men, with an average age at presentation of around 50 years.

The pain associated with Morton neuroma is usually throbbing, burning, or shooting, and localized to the plantar aspect of the foot. It is typically located between the 3rd and 4th metatarsal heads, although it may appear in other proximal locations. The pain may radiate to the toes and can be associated with paresthesia. The pain can be severe, and the condition may become debilitating to the extent that patients are apprehensive about walking or touching their foot to the ground. It is aggravated by walking in shoes with a narrow toe box or high heels that cause excessive pronation and excessive forefoot pressure; removal of tight shoes typically relieves the pain.

### **Diagnosis**

Although a host of imaging methods are used to diagnosis Morton neuroma, including plain radiographs, magnetic resonance imaging, and ultrasonography, objective findings are unique to this condition and are primarily used to establish a clinical diagnosis. Thus, a patient's toes often show splaying or divergence. Patients may describe the feeling of a "lump" on the foot bottom or a feeling of walking on a rolled-up or wrinkled sock. Clinical examination with medial and lateral compression may reproduce the painful symptoms with a palpable "click" on interspace compression (Mulder sign).

### **Treatment**

Management of patients diagnosed with Morton neuroma typically starts with conservative approaches, such as the use of metatarsal pads in shoes and orthotic devices that alter supination and pronation of the affected foot. These approaches try to reduce pressure and irritation of the affected nerve. They may provide relief, but do not alter the underlying pathology. There is scant evidence to support the effectiveness or comparative effectiveness of these practices. In a case series, Bennett et al (1995) evaluated a 3-stage protocol of "stepped care" through which private practice patients (N=115) advanced from stage I (education plus footwear modifications, and a metatarsal pad) to stage II (steroid injections with local anesthetic or local anesthetic alone), and into stage III (surgical resection) if stages I and II were not relieved within 3 months. Overall, 97 (85%) of 115 patients believed that pain had been reduced with the treatment program. However, 24 (21%) patients eventually required surgical excision of the nerve, and 23 (96%) of them had satisfactory results.

### **Minimally Invasive Ablation Procedures**

Several minimally invasive procedures to treat refractory Morton and other peripheral neuromas are aimed at in situ destruction of the pathology, including intralesional alcohol injection, radiofrequency ablation (RFA) and cryoablation (also known as cryoneurolysis, cryolysis, and cryoanalgesia).

Dehydrated ethanol has been shown to inhibit nerve function in vitro, has high affinity for nerve tissue, and causes direct damage to nerve cells via dehydration, cell necrosis, and precipitation of protoplasm, leading to neuritis and a pattern of Wallerian degeneration. Technically, ethanol is a sclerosant that causes chemical neurolysis of the nerve pathology but is considered an ablative procedure for this evidence review. The use of ultrasound guidance during this procedure has been shown to increase surgical accuracy, improve outcomes, and shorten procedure duration. RFA uses heat generated by an electrode that conducts electromagnetic energy into a tissue or lesion to denature proteins and destroy cells. RFA is used to ablate a wide range of tissues or lesions, including osteoid osteoma; cardiovascular system pathologies; cervical pain syndromes; liver, lung, and other cancers; and varicosities. Cryoablation uses coolant to chill a cryoprobe to temperatures

below  $-75^{\circ}\text{C}$ , which when inserted into a lesion, freezes and kills the tissue. It has been used to treat Morton neuroma, other chronic nerve pain syndromes, and conditions for which RFA has been used.

For individuals who have knee osteoarthritis (OA) who receive radiofrequency ablation (RFA) of peripheral nerves, the evidence includes systematic reviews of randomized controlled trials (RCTs), RCTs with 24 to 200 individuals, and non-randomized comparative studies with up to 12 months of follow-up. Relevant outcomes include symptoms, functional outcomes, and quality of life (QOL). Knee OA is a common disorder in older adults. RFA of the genicular nerves has the potential to alleviate pain and improve function in this population, and might also delay or eliminate the need for total knee arthroplasty (TKA). At this time, there is high heterogeneity in methods and comparators. The systematic reviews generally found that RFA had a benefit on pain, function, and composite scores compared to the control treatments at 3 and 6-month follow-up; however, most estimates were determined to have moderate to high heterogeneity. The network meta-analysis compared multiple RFA modalities and found that cooled RFA had significantly improved efficacy for pain and function through 6 months follow-up compared with traditional or pulsed RFA. The 2 multicenter trials conducted in the U.S. used anesthetic nerve block under fluoroscopic guidance and compared efficacy of cooled RFA to either steroid injection or hyaluronic acid injection. Both studies reported a responder rate of approximately 70% at 6 months, which was significantly greater than the control conditions. A small, double-blind RCT of bipolar RFA with genicular nerve block compared to genicular nerve block and sham RFA found no differences between groups for visual analog score (VAS) pain or the Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores through 12 months follow-up. Given that OA of the knee is a common condition; adequately powered studies, preferably blinded with active and sham controls and follow-up of at least 12 months, is needed to determine the benefits and potential harms of this treatment. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have knee OA or TKA who receive cryoneurolysis of peripheral nerves, the evidence includes 2 RCTs with a total of 304 participants, a comparative, retrospective cohort study of 57 participants, and a registry study of 140 individuals. Relevant outcomes include symptoms, functional outcomes, and QOL. In one RCT, cryoneurolysis in individuals with knee OA resulted in a greater decrease in WOMAC pain score, WOMAC total score, and VAS score at 30 days compared with sham-treated controls. However, subsequent measurements showed no significant benefit of cryoneurolysis on WOMAC score at 60 days or VAS scores at 60 or 90 days. Another RCT investigated cryoneurolysis compared to standard of care for patients with knee OA who were planning to undergo TKA. Cryoneurolysis resulted in a lower rate of opioid consumption, a reduction in numeric rating scale (NRS) pain scores, and Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR) functional performance at 12 weeks post discharge. The retrospective cohort study reported superiority of cryoneurolysis on the KOOS JR and Short Form-12 item (SF-12) mental score at 1 year follow-up; no significant differences were observed on the SF-12 physical score at 1 year follow-up or for any outcome at earlier 3 month assessment. A registry study found improved pain and lowered opioid use with cryoneurolysis prior to TKA; however, functional outcomes through 6 months were similar. Several technical issues including the optimal number of applications for each nerve, the duration of treatment, and the duration of thawing before moving the cannula have not been resolved. The most effective method for determining probe insertion location (eg, ultrasound-guided or based on anatomic landmarks) also needs to be established. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have plantar fasciitis who receive RFA of peripheral nerves, the evidence includes 2 RCTs and a meta-analysis. Relevant outcomes include symptoms, functional outcomes, and QOL. The meta-analysis pooled evidence from 2 RCTs and did not demonstrate a significant improvement in pain outcomes compared to the control group. The analysis revealed significant heterogeneity, and the overall quality of evidence was graded as low. One of the randomized trials only evaluated 17 individuals, and assessment of randomized outcomes was limited to 4 weeks post-treatment. A second RCT evaluated 36 individuals out to 12 weeks. Both trials found RFA associated with pain reduction, but to be more confident in the efficacy of this treatment, controlled trials with larger samples and longer follow-up would be necessary. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have occipital neuralgia or cervicogenic headache who receive RFA or cryoneurolysis of peripheral nerves, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, functional outcomes, and QOL. No RCTs of RFA for chronic occipital neuralgia have been identified. Three RCTs of RFA for a cervicogenic headache have been published, none of which were high quality. Pain is a subjective, patient-reported measure that is particularly susceptible to a placebo effect. Randomized trials with sham or active-controls are needed to evaluate the efficacy of this treatment. One controlled trial found a temporary benefit of cryoneurolysis for cervicogenic headache, but the effect was not significantly better than injection of corticosteroid and local anesthetic. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have Morton neuroma who receive intralesional alcohol injection(s), the evidence includes retrospective case series. Relevant outcomes are symptoms, functional outcomes, and treatment-related morbidity. The body of evidence is limited, consisting of case series reporting on the treatment response of patients with refractory Morton neuroma. The available case series have generally reported that some patients experience pain relief and express satisfaction with the procedure. Some evidence has suggested that surgery after failed cases of alcohol injections is more complex and challenging than in untreated patients due to the presence of fibrosis. There is a lack of controlled trials comparing alcohol injections with alternative therapies, and there are no controlled studies comparing outcomes for alcohol injections with those for surgery in surgical candidates. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have Morton neuroma who receive radiofrequency ablation (RFA), the evidence includes a systematic review and case series. Relevant outcomes are symptoms, functional outcomes, and treatment-related morbidity. The body of evidence is highly heterogeneous regarding RFA protocols, descriptions of prior conservative management, patient characteristics, follow-up durations, outcome measures, and reporting of outcomes. Variable proportions of patients require surgery after RFA, making the benefit of RFA for avoiding more invasive treatment uncertain. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have Morton neuroma who receive cryoablation, the evidence includes case series. Relevant outcomes are symptoms, functional outcomes, and treatment-related morbidity. Only retrospective case series on the use of cryoablation to treat peripheral nerve pain were identified in a literature review. The case series were heterogeneous regarding cryoablation protocols and length of follow-up. Outcome measures did not provide information on functional endpoints. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have peripheral neuroma(s) other than Morton neuroma who receive ablation no published literature was identified. Relevant outcomes are symptoms, functional outcomes, and treatment-related morbidity. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## **CODING**

The following code may be considered medically necessary for Medicare Advantage Plans and Commercial Products when the medical criteria in the online authorization tool is met:

**64640** Destruction by neurolytic agent; other peripheral nerve or branch

The following code is covered for Medicare Advantage Plans and is not medically necessary for Commercial Products:

**64624** Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed

The following codes are not covered for Medicare Advantage Plans and not medically necessary for Commercial Products:

- 64632** Destruction by neurolytic agent; plantar common digital nerve
- 0440T** Ablation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve
- 0441T** Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve
- 0442T** Ablation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (eg, brachial plexus, pudendal nerve)

The following codes may be considered medically necessary for Medicare Advantage Plans when the associated procedure is determined to be medically necessary AND when the criteria in the Medical Necessity policy is met, and are not medically necessary for Commercial Products:

- C9808** Nerve cryoablation probe (e.g., cryoICE, cryoSPHERE, cryoSPHERE MAX, cryo2), including probe and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023)
- C9809** Cryoablation needle (e.g., iovera system), including needle/tip and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023)

## RELATED POLICIES

Medical Necessity

Prior Authorization for Services, Treatments or Procedures

## PUBLISHED

Provider Update, March 2026

## REFERENCES

1. Chua NH, Vissers KC, Sluijter ME. Pulsed radiofrequency treatment in interventional pain management: mechanisms and potential indications-a review. *Acta Neurochir (Wien)*. Apr 2011; 153(4): 763-71. PMID21116663
2. Oladeji LO, Cook JL. Cooled Radio Frequency Ablation for the Treatment of Osteoarthritis-Related Knee Pain: Evidence, Indications, and Outcomes. *J Knee Surg*. Jan 2019; 32(1): 65-71. PMID30396206
3. Jamison DE, Cohen SP. Radiofrequency techniques to treat chronic knee pain: a comprehensive review of anatomy, effectiveness, treatment parameters, and patient selection. *J Pain Res*. 2018; 11: 1879-1888. PMID 30271194
4. Michael JW, Schlüter-Brust KU, Eysel P. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee. *Dtsch Arztebl Int*. Mar 2010; 107(9): 152-62. PMID 20305774
5. Chen AF, Mullen K, Casambre F, et al. Thermal Nerve Radiofrequency Ablation for the Nonsurgical-Treatment of Knee Osteoarthritis: A Systematic Literature Review. *J Am Acad Orthop Surg*. May 012021; 29(9): 387-396. PMID 32701684
6. Choi WJ, Hwang SJ, Song JG, et al. Radiofrequency treatment relieves chronic knee osteoarthritis pain: a double-blind randomized controlled trial. *Pain*. Mar 2011; 152(3): 481-487. PMID 21055873
7. Sari S, Aydin ON, Turan Y, et al. Which one is more effective for the clinical treatment of chronic pain in knee osteoarthritis: radiofrequency neurotomy of the genicular nerves or intra-articular injection?. *Int J Rheum Dis*. Oct 2018; 21(10): 1772-1778. PMID 27515095
8. Ray D, Goswami S, Dasgupta SR, Ray S, Basu S. Intra-articular hyaluronic acid injection versus RF ablation of genicular nerve for knee osteoarthritis pain: A randomized open-label, clinical study. *Indian J Pain*. 2018; 32:36-9.
9. Davis T, Loudermilk E, DePalma M, et al. Prospective, Multicenter, Randomized, Crossover Clinical Trial Comparing the Safety and Effectiveness of Cooled Radiofrequency Ablation With Corticosteroid Injection in the Management of Knee Pain From Osteoarthritis. *Reg Anesth Pain Med*. Jan 2018; 43(1):84-91. PMID 29095245
10. El-Hakeim EH, Elawamy A, Kamel EZ, et al. Fluoroscopic Guided Radiofrequency of Genicular Nerves for Pain Alleviation in Chronic Knee Osteoarthritis: A Single-Blind Randomized Controlled Trial. *Pain Physician*. Mar 2018; 21(2): 169-177. PMID 29565947

11. Shen WS, Xu XQ, Zhai NN, et al. Radiofrequency Thermocoagulation in Relieving Refractory Pain of Knee Osteoarthritis. *Am J Ther.* 2017; 24(6): e693-e700. PMID 26938761
12. Xiao L, Shu F, Xu C, et al. Highly selective peripheral nerve radio frequency ablation for the treatment of severe knee osteoarthritis. *Exp Ther Med.* Nov 2018; 16(5): 3973-3977. PMID 30344675
13. Liu J, Wang T, Zhu ZH. Efficacy and safety of radiofrequency treatment for improving knee pain and function in knee osteoarthritis: a meta-analysis of randomized controlled trials. *J Orthop Surg Res.* Jan15 2022; 17(1): 21. PMID 35033150
14. Wu L, Li Y, Si H, et al. Radiofrequency Ablation in Cooled Monopolar or Conventional Bipolar Modality Yields More Beneficial Short-Term Clinical Outcomes Versus Other Treatments for Knee Osteoarthritis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. *Arthroscopy.* Jul2022; 38(7): 2287-2302. PMID 35157969
15. McCormick ZL, Reddy R, Korn M, et al. A Prospective Randomized Trial of Prognostic Genicular Nerve Blocks to Determine the Predictive Value for the Outcome of Cooled Radiofrequency Ablation for Chronic Knee Pain Due to Osteoarthritis. *Pain Med.* Aug 01 2018; 19(8): 1628-1638. PMID 29300971
16. Davis T, Loudermilk E, DePalma M, et al. Twelve-month analgesia and rescue, by cooled radiofrequency ablation treatment of osteoarthritic knee pain: results from a prospective, multicenter, randomized, cross-over trial. *Reg Anesth Pain Med.* Feb 16 2019. PMID 30772821
17. Hunter C, Davis T, Loudermilk E, et al. Cooled Radiofrequency Ablation Treatment of the Genicular Nerves in the Treatment of Osteoarthritic Knee Pain: 18- and 24-Month Results. *Pain Pract.* Mar 2020;20(3): 238-246. PMID 31605667
18. Chen AF, Khalouf F, Zora K, et al. Cooled radiofrequency ablation provides extended clinical utility in the management of knee osteoarthritis: 12-month results from a prospective, multi-center, randomized, cross-over trial comparing cooled radiofrequency ablation to a single hyaluronic acid injection. *BMC Musculoskelet Disord.* Jun 09 2020; 21(1): 363. PMID 32517739
19. American Academy of Orthopaedic Surgeons. Management of Osteoarthritis of the Knee (Non-Arthroplasty) Evidence-Based Clinical Practice Guideline. August 31, 2021. Accessed July 22, 2024.
20. Lyman J, Khalouf F, Zora K, et al. Cooled radiofrequency ablation of genicular nerves provides 24-Month durability in the management of osteoarthritic knee pain: Outcomes from a prospective, multicenter, randomized trial. *Pain Pract.* Jul 2022; 22(6): 571-581. PMID 35716058
21. Elawamy A, Kamel EZ, Mahran SA, et al. Efficacy of Genicular Nerve Radiofrequency Ablation Versus Intra-Articular Platelet Rich Plasma in Chronic Knee Osteoarthritis: A Single-Blind Randomized Clinical Trial. *Pain Physician.* Mar 2021; 24(2): 127-134. PMID 33740345
22. Malaithong W, Tontisirin N, Seangrungs R, et al. Bipolar radiofrequency ablation of the superomedial(SM), superolateral (SL) and inferomedial (IM) genicular nerves for chronic osteoarthritis knee pain: a randomized double-blind placebo-controlled trial with 12-month follow-up. *Reg Anesth Pain Med.* Dec21 2022; 48(4): 151-60. PMID 36543391
23. Ma Y, Chen YS, Liu B, et al. Ultrasound-Guided Radiofrequency Ablation for Chronic Osteoarthritis Knee Pain in the Elderly: A Randomized Controlled Trial. *Pain Physician.* Mar 2024; 27(3): 121-128. PMID 38506679
24. Kapural L, Minerali A, Sanders M, et al. Cooled Radiofrequency Ablation Provides Prolonged Pain Relief Compared to Traditional Radiofrequency Ablation: A Real-World, Large Retrospective Clinical Comparison from a Single Practice. *J Pain Res.* 2022; 15: 2577-2586. PMID 36068792
25. Wu BP, Grits D, Foorsov V, et al. Cooled and traditional thermal radiofrequency ablation of genicular nerves in patients with chronic knee pain: a comparative outcomes analysis. *Reg Anesth Pain Med.* Aug03 2022. PMID 35922077
26. McCormick ZL, Patel J, Conger A, et al. The Safety of Genicular Nerve Radiofrequency Ablation. *Pain Med.* Feb 23 2021; 22(2): 518-519. PMID 33517427
27. Radnovich R, Scott D, Patel AT, et al. Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial. *Osteoarthritis Cartilage.* Aug 2017; 25(8): 1247-1256. PMID 28336454
28. Mihalko WM, Kerkhof AL, Ford MC, et al. Cryoneurolysis before Total Knee Arthroplasty in Patients With Severe Osteoarthritis for Reduction of Postoperative Pain and Opioid Use in a Single-Center Randomized Controlled Trial. *J Arthroplasty.* May 2021; 36(5): 1590-1598. PMID 33279353

29. Lung BE, Karasavvidis T, Sharma AK, et al. Cryoneurolysis Is a Safe, Effective Modality to Improve Rehabilitation after Total Knee Arthroplasty. *Life (Basel)*. Aug 29 2022; 12(9). PMID 36143381
30. Mont MA, Lin JH, Spitzer AI, et al. Cryoneurolysis Associated With Improved Pain, Function, and Sleep in Patients Following total Knee Arthroplasty: Use of a New Real-World Registry. *J Arthroplasty*. Jun 26 2024. PMID 38942249
31. Gabriel RA, Ilfeld BM. Novel Methodologies in Regional Anesthesia for Knee Arthroplasty. *Anesthesiol Clin*. Sep 2018; 36(3): 387-401. PMID 30092936
32. Guimarães JS, Arcanjo FL, Leporace G, et al. Effects of therapeutic interventions on pain due to plantar fasciitis: A systematic review and meta-analysis. *Clin Rehabil*. Jun 2023; 37(6): 727-746. PMID36571559
33. Wu YT, Chang CY, Chou YC, et al. Ultrasound-Guided Pulsed Radiofrequency Stimulation of Posterior Tibial Nerve: A Potential Novel Intervention for Recalcitrant Plantar Fasciitis. *Arch Phys Med Rehabil*. May 2017; 98(5): 964-970. PMID 28209507
34. Landsman AS, Catanese DJ, Wiener SN, et al. A prospective, randomized, double-blinded study with crossover to determine the efficacy of radio-frequency nerve ablation for the treatment of heel pain. *J Am Podiatr Med Assoc*. 2013; 103(1): 8-15. PMID 23328847
35. Kurtoglu A, Kochai A, Inanmaz ME, et al. Effectiveness of radiofrequency ablation for treatment of plantar fasciitis. *Medicine (Baltimore)*. Mar 25 2022; 101(12): e29142. PMID 35357356
36. Cozzarelli J, Sollitto RJ, Thapar J, et al. A 12-year long-term retrospective analysis of the use of radiofrequency nerve ablation for the treatment of neurogenic heel pain. *Foot Ankle Spec*. Dec 2010;3(6): 338-46. PMID 20817845
37. Grandhi RK, Kaye AD, Abd-Elsayed A. Systematic Review of Radiofrequency Ablation and Pulsed Radiofrequency for Management of Cervicogenic Headaches. *Curr Pain Headache Rep*. Feb 23 2018;22(3): 18. PMID 29476360
38. Ducic I, Felder JM, Fantus SA. A systematic review of peripheral nerve interventional treatments for chronic headaches. *Ann Plast Surg*. Apr 2014; 72(4): 439-45. PMID 24374395
39. Kvarstein G, Högström H, Allen SM, et al. Cryoneurolysis for cervicogenic headache - a double blinded randomized controlled study. *Scand J Pain*. Dec 18 2019; 20(1): 39-50. PMID 31675351
40. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Rheumatol*. Feb 2020; 72(2): 220-233. PMID 31908163
41. Schneider HP, Baca JM, Carpenter BB, et al. American College of Foot and Ankle Surgeons Clinical Consensus Statement: Diagnosis and Treatment of Adult Acquired Infracalcaneal Heel Pain. *J Foot Ankle Surg*. 2018; 57(2): 370-381. PMID 29284574
42. Lee DW, Pritzlaff S, Jung MJ, et al. Latest Evidence-Based Application for Radiofrequency Neurotomy(LEARN): Best Practice Guidelines from the American Society of Pain and Neuroscience (ASPN). *J Pain Res*. 2021; 14: 2807-2831. PMID 34526815
43. Rajput K, Reddy S, Shankar H. Painful neuromas. *Clin J Pain*. Sep 2012; 28(7): 639-45. PMID22699131
44. Jain S, Mannan K. The diagnosis and management of Morton's neuroma: a literature review. *Foot Ankle Spec*. Aug 2013; 6(4): 307-17. PMID 23811947
45. Thomas JL, Blich EL, Chaney DM, et al. Diagnosis and treatment of forefoot disorders. Section 3.Morton's intermetatarsal neuroma. *J Foot Ankle Surg*. 2009; 48(2): 251-6. PMID 19232980
46. Wu KK. Morton's interdigital neuroma: a clinical review of its etiology, treatment, and results. *J Foot Ankle Surg*. 1996; 35(2): 112-9; discussion 187-8. PMID 8722878
47. MULDER JD. The causative mechanism in morton's metatarsalgia. *J Bone Joint Surg Br*. Feb 1951; 33-B(1): 94-5. PMID 14814167
48. Adams WR. Morton's neuroma. *Clin Podiatr Med Surg*. Oct 2010; 27(4): 535-45. PMID 20934103
49. Thomson CE, Gibson JN, Martin D. Interventions for the treatment of Morton's neuroma. *Cochrane Database Syst Rev*. 2004; 2004(3): CD003118. PMID 15266472
50. Bennett GL, Graham CE, Mauldin DM. Morton's interdigital neuroma: a comprehensive treatment protocol. *Foot Ankle Int*. Dec 1995; 16(12): 760-3. PMID 8749346
51. Dierselhuis EF, van den Eerden PJ, Hoekstra HJ, et al. Radiofrequency ablation in the treatment of cartilaginous lesions in the long bones: results of a pilot study. *Bone Joint J*. Nov 2014; 96-B(11): 1540-5. PMID 25371471

52. Boersma D, van Eekeren RR, Kelder HJ, et al. Mechanochemical endovenous ablation versus radiofrequency ablation in the treatment of primary small saphenous vein insufficiency (MESSI trial):study protocol for a randomized controlled trial. *Trials*. Oct 29 2014; 15: 421. PMID 25354769
53. Di Costanzo GG, Tortora R, D'Adamo G, et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. *J Gastroenterol Hepatol*. Mar 2015; 30(3): 559-65. PMID 25251043
54. Anchala PR, Irving WD, Hillen TJ, et al. Treatment of metastatic spinal lesions with a navigational bipolar radiofrequency ablation device: a multicenter retrospective study. *Pain Physician*. 2014; 17(4):317-27. PMID 25054391
55. Hillen TJ, Anchala P, Friedman MV, et al. Treatment of metastatic posterior vertebral body osseous tumors by using a targeted bipolar radiofrequency ablation device: technical note. *Radiology*. Oct 2014;273(1): 261-7. PMID 24927327
56. Wang X, Wang X, Song Y, et al. Efficiency of radiofrequency ablation for surgical treatment of chronic atrial fibrillation in rheumatic valvular disease. *Int J Cardiol*. Jul 01 2014; 174(3): 497-502. PMID24820759
57. Huang WZ, Wu YM, Ye HY, et al. Comparison of the outcomes of monopolar and bipolar radiofrequency ablation in surgical treatment of atrial fibrillation. *Chin Med Sci J*. Mar 2014; 29(1): 28-32. PMID24698675
58. Avery J, Kumar K, Thakur V, et al. Radiofrequency ablation as first-line treatment of varicose veins. *AmSurg*. Mar 2014; 80(3): 231-5. PMID 24666862
59. Hiraki T, Gobara H, Iguchi T, et al. Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer. *World J Gastroenterol*. Jan 28 2014; 20(4): 988-96. PMID 24574771
60. Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. *JAMA*. Feb 19 2014; 311(7):692-700. PMID 24549549
61. Fuller CW, Nguyen SA, Lohia S, et al. Radiofrequency ablation for treatment of benign thyroid nodules: systematic review. *Laryngoscope*. Jan 2014; 124(1): 346-53. PMID 24122763
62. Huang XM, Hu JQ, Li ZF, et al. Symptomatic sinus tachycardia with perpetuating slow pathway: successful treatment with radiofrequency ablation. *Pacing Clin Electrophysiol*. Oct 2014; 37(10): e1-4. PMID 21077914
63. Prologo JD, Passalacqua M, Patel I, et al. Image-guided cryoablation for the treatment of painful musculoskeletal metastatic disease: a single-center experience. *Skeletal Radiol*. Nov 2014; 43(11):1551-9. PMID 24972918
64. Kim EH, Tanagho YS, Saad NE, et al. Comparison of laparoscopic and percutaneous cryoablation for treatment of renal masses. *Urology*. May 2014; 83(5): 1081-7. PMID 24560975
65. Durand M, Barret E, Galiano M, et al. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. *BJU Int*. Jan 2014; 113(1): 56-64. PMID 24053685
66. Duarte R, Pereira T, Pinto P, et al. [Percutaneous Image-guided cryoablation for localized bone plasmacytoma treatment]. *Radiologia*. 2014; 56(5): e1-4. PMID 22621822
67. Rodriguez-Entem FJ, Expósito V, Gonzalez-Enriquez S, et al. Cryoablation versus radiofrequency ablation for the treatment of atrioventricular nodal reentrant tachycardia: results of a prospective randomized study. *J Interv Card Electrophysiol*. Jan 2013; 36(1): 41-5; discussion 45. PMID 23080326
68. Yamauchi Y, Izumi Y, Hashimoto K, et al. Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer. *PLoS One*. 2012; 7(3): e33223. PMID 22413004
69. Collins KK, Schaffer MS. Use of cryoablation for treatment of tachyarrhythmias in 2010: survey of current practices of pediatric electrophysiologists. *Pacing Clin Electrophysiol*. Mar 2011; 34(3): 304-8. PMID 21077912
70. Kaufman CS, Bachman B, Littrup PJ, et al. Cryoablation treatment of benign breast lesions with 12-month follow-up. *Am J Surg*. Oct 2004; 188(4): 340-8. PMID 15474424
71. Pasquali C, Vulcano E, Novario R, et al. Ultrasound-guided alcohol injection for Morton's neuroma. *Foot Ankle Int*. Jan 2015; 36(1): 55-9. PMID 25367249
72. Perini L, Perini C, Tagliapietra M, et al. Percutaneous alcohol injection under sonographic guidance in Morton's neuroma: follow-up in 220 treated lesions. *Radiol Med*. Jul 2016; 121(7): 597-604. PMID26883232
73. Musson RE, Sawhney JS, Lamb L, et al. Ultrasound guided alcohol ablation of Morton's neuroma. *Foot Ankle Int*. Mar 2012; 33(3): 196-201. PMID 22734280

74. Hughes RJ, Ali K, Jones H, et al. Treatment of Morton's neuroma with alcohol injection under sonographic guidance: follow-up of 101 cases. *AJR Am J Roentgenol.* Jun 2007; 188(6): 1535-9. PMID17515373
75. Fanucci E, Masala S, Fabiano S, et al. Treatment of intermetatarsal Morton's neuroma with alcohol injection under US guide: 10-month follow-up. *Eur Radiol.* Mar 2004; 14(3): 514-8. PMID 14531002
76. Morgan P, Monaghan W, Richards S. A systematic review of ultrasound-guided and non-ultrasound-guided therapeutic injections to treat Morton's neuroma. *J Am Podiatr Med Assoc.* Jul 2014; 104(4):337-48. PMID 25076076
77. Dockery GL. The treatment of intermetatarsal neuromas with 4% alcohol sclerosing injections. *J Foot Ankle Surg.* 1999; 38(6): 403-8. PMID 10614611
78. Llombart-Blanco R, Mariscal G, Benlloch M, et al. Systematic Review and Meta-analysis of Radiofrequency Ablation for Morton's Neuroma: Outcomes and Predictors of Success. *Am J Phys Med Rehabil.* May 01 2025; 104(5): 465-472. PMID 39642322
79. Genon MP, Chin TY, Bedi HS, et al. Radio-frequency ablation for the treatment of Morton's neuroma. *ANZ J Surg.* Sep 2010; 80(9): 583-5. PMID 20857612
80. Moore JL, Rosen R, Cohen J, et al. Radiofrequency thermos neurolysis for the treatment of Morton's neuroma. *J Foot Ankle Surg.* 2012; 51(1): 20-2. PMID 22055491
81. Chuter GS, Chua YP, Connell DA, et al. Ultrasound-guided radiofrequency ablation in the management of interdigital (Morton's) neuroma. *Skeletal Radiol.* Jan 2013; 42(1): 107-11. PMID 23073898
82. Connors JC, Boike AM, Rao N, et al. Radiofrequency Ablation for the Treatment of Painful Neuroma. *JFoot Ankle Surg.* 2020; 59(3): 457-461. PMID 32354501
83. Friedman T, Richman D, Adler R. Sonographically guided cryoneurolysis: preliminary experience and clinical outcomes. *J Ultrasound Med.* Dec 2012; 31(12): 2025-34. PMID 23197557
84. Cazzato RL, Garnon J, Ramamurthy N, et al. Percutaneous MR-Guided Cryoablation of Morton's Neuroma: Rationale and Technical Details After the First 20 Patients. *Cardiovasc Intervent Radiol.* Oct2016; 39(10): 1491-8. PMID 27189181
85. Moulin B, Angelopoulos G, Sarrazin JL, et al. Safety and Efficacy of Percutaneous Morton Neuroma Cryoneurolysis Under Ultrasound Guidance. *Cardiovasc Intervent Radiol.* Jun 2024; 47(6): 795-800. PMID 38438685
86. The Association of Extremity Nerve Surgeons Clinical Practice Guidelines v. 2.0. 2020. Accessed April22, 2025.

**CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS**

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

